ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase

This study tests a combination of three drugs — ASTX727 (a pill form of decitabine, a chemotherapy), dasatinib (a targeted therapy), and another agent — as a new first-line treatment for people with a type of leukemia called Philadelphia chromosome-positive Chronic Myeloid Leukemia (CML) in the early chronic phase. **You may be eligible if...** - You have been newly diagnosed with CML that is Philadelphia chromosome-positive (Ph+) or BCR-ABL positive - Your diagnosis is within the past 12 months - You have received little or no prior treatment (less than 1 month of an FDA-approved TKI drug) **You may NOT be eligible if...** - You have had CML for more than 12 months before starting the study - You have already received significant prior treatment for CML (more than 1 month of a TKI) - Your leukemia has progressed beyond the early chronic phase Talk to your doctor to see if this trial is right for you.